Alnylam Pharmaceuticals, Inc.
ALNY
$292.03
$7.192.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 1,228.66% | 322.56% | 325.05% | -292.43% | 72.32% |
| Total Depreciation and Amortization | -5.91% | -4.67% | -1.28% | -7.06% | 6.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 44.96% | -55.80% | 164.16% | -5.12% | 29.25% |
| Change in Net Operating Assets | -35.92% | 32.45% | -598.92% | 230.57% | -101.96% |
| Cash from Operations | 158.60% | 272.78% | 643.84% | 23.82% | -47.59% |
| Capital Expenditure | -143.40% | -156.12% | -189.65% | -78.26% | 30.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -103.02% | 68.34% | 2,069.64% | -402.89% | 324.60% |
| Cash from Investing | -122.45% | 29.76% | 1,756.55% | -516.56% | 268.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -73.35% | 14.95% | -28.04% | -38.83% | 90.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 177.89% | 1,170.82% | -507.38% | -2,042.36% | -207.57% |
| Cash from Financing | -65.90% | 46.20% | -536.33% | -59.12% | 59.39% |
| Foreign Exchange rate Adjustments | -150.25% | 66.99% | -106.14% | 981.60% | 241.41% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.03% | 224.03% | 187.07% | -67.32% | 141.18% |